ReviewFrontiers in medicine2021
Gut Microbiota Dysbiosis Is a Crucial Player for the Poor Outcomes for COVID-19 in Elderly, Diabetic and Hypertensive Patients.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Viable gut bacterial metrics associated with intestinal eubiosis and dysbiosis.Gut microbes reports · 2026Article
- Metaproteomics reveals age-specific alterations of gut microbiome in hamsters with SARS-CoV-2 infection.Gut microbes · 2025Article
- Gut microbiota is involved in the exacerbation of adrenal glucocorticoid steroidogenesis in diabetic animals by activation of the TLR4 pathway.Frontiers in endocrinology · 2025Article
- The association between the dietary index for gut microbiota and frailty: a cross-sectional study.Frontiers in nutrition · 2025Article
- Observational
- Nutrition at the Intersection between Gut Microbiota Eubiosis and Effective Management of Type 2 Diabetes.Nutrients · 2024Review
- Gut Microbiota Modulation by Selenium and Zinc Enrichment Postbiotic on Dysbiosis Associated with Hypertension.Current vascular pharmacology · 2024Article
- Blood circulating bacterial DNA in hospitalized old COVID-19 patients.Immunity & ageing : I & A · 2023Article
- The role of serum circulating microbial toxins in severity and cytokine storm of COVID positive patients.Microbial pathogenesis · 2023Review
- Regulatory effect of gut microbes on blood pressure.Animal models and experimental medicine · 2022Review
- Profiling of exhaled volatile organics in the screening scenario of a COVID-19 test center.iScience · 2022Article
- The role of the gut microbiota in health and cardiovascular diseases.Molecular biomedicine · 2022Review
- Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm.Microbial pathogenesis · 2022Review
- Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity.World journal of gastroenterology · 2022Review
- Review
- Human Milk Oligosaccharides: Potential Applications in COVID-19.Biomedicines · 2022Review
- Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin.Frontiers in microbiology · 2022Review
- Earth Dreams: Reimagining ARPA for Health of People, Places and Planet.International journal of environmental research and public health · 2021Article
- Leptin in the Respiratory Tract: Is There a Role in SARS-CoV-2 Infection?Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new infectious disease, named COVID-19, caused by the coronavirus associated to severe acute respiratory syndrome (SARS-CoV-2) has become pandemic in 2020. The three most common pre-existing comorbidities associated with COVID-19-related death are elderly, diabetic, and hypertensive people. A common factor among these risk groups for the outcome of death in patients infected with SARS-CoV-2 is dysbiosis, with an increase in the proportion of bacteria with a pro-inflammatory profile. Due to this dysbiosis, elderly, diabetic, and hypertensive people present a higher propensity to mount an inflammatory environment in the gut with poor immune editing, culminating in a weakness of the intestinal permeability barrier and high bacterial product translocation to the bloodstream. This scenario culminates in a low-grade, persistent, and systemic inflammation. In this context, we propose here that high circulating levels of bacterial products, like lipopolysaccharide (LPS), can potentiate the SARS-CoV-2-induced cytokines, including IL-6, being crucial for development of the cytokine storm in the severe form of the disease. A better understanding on the possible correlation between gut dysbiosis and poor outcomes observed in elderly, diabetic, and hypertensive people can be useful for the development of new therapeutic strategies based on modulation of the gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.